The M2 marker CD206 was significantly decreased in the tumor tissue (p = 0.012), and down-regulation of TGF-β occurred in HCC tissue treated with sorafenib (p = 0.02). The gene discussed is TGFB1; the disease is hepatocellular carcinoma.